<DOC>
	<DOCNO>NCT00154271</DOCNO>
	<brief_summary>The study compare efficacy aggressive versus moderate initial antihypertensive regimen reduce blood pressure patient Stage 2 hypertension . Additionally , study examines effect blood pressure reduction level high sensitivity hsCRP . Although main goal determine overall effect blood pressure reduction hsCRP level , analysis also evaluate whether aggressive antihypertensive regimen effective moderate one reduce hsCRP level .</brief_summary>
	<brief_title>Effects Blood Pressure Reduction High Sensitivity C-Reactive Protein ( hsCRP )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . Stage 2 hypertension define mean three ( 3 ) repeat seat BP measurement : SBP 160 185 mmHg , inclusive and/or DBP 100 109 mmHg , inclusive . 2 . Patients must documentation serum creatinine equal &lt; 2.0 mg/dL , serum potassium equal &gt; 3.5 equal &lt; 5.5 mmol/L , serum AST ALT &lt; 2xULN obtain within 3 month prior Visit 1 . 3 . Patients must documentation HbA1C equal &lt; 11.0 % obtain within 1 month prior Visit 1 . 1 . History secondary hypertension . 2 . Pharmacologic antihypertensive therapy ACE inhibitor , angiotensin receptor blocker , aldosterone blocker within 3 month prior Visit 1 , thiazide diuretic within 1 month prior Visit 1 . The use class agent low BP use therapy HTN , allow long agent start least 3 month prior randomization , initiate enrollment dos remain unchanged study . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>Hypertension ( HTN )</keyword>
	<keyword>High Sensitivity C-Reactive Protein</keyword>
</DOC>